<DOC>
	<DOCNO>NCT00444743</DOCNO>
	<brief_summary>The purpose study evaluate tolerability , pharmacokinetics , pharmacodynamics , biologic activity MM-093 patient moderate severe uveitis .</brief_summary>
	<brief_title>Phase 2 Study MM-093 Treat Patients With Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Aged 18 year Understand , sign , date write voluntary informed consent form screen visit prior protocol specific procedure perform . Have diagnose sarcoid birdshot uveitis Be able willing comply study visit procedure per protocol . Women child bear potential must use medically acceptable mean birth control effective manner agree continue use study 6 week last dose study drug . Sexually active men must agree use medically acceptable form contraception study continue 4 week last dose study drug . Able store patient kit/cooler contain study drug refrigerator home . Significant concurrent medical disease include : Cancer history cancer , lymphoproliferative disorder ( sarcoidosis successfully resect cutaneous basal squamous cell carcinoma ) within 5 year screen visit . Any condition participation study judge physician detrimental patient , history significant unstable cardiac , pulmonary , gastrointestinal , neurological , psychiatric disease . Significant ongoing infection require systemic antibiotic , antifungal , antiviral , ant antimycobacterial therapy . Autoimmune connective tissue disorder sarcoid birdshot uveitis , ( e.g . Rheumatoid Arthritis , Systemic Lupus Erythematosus , Scleroderma . ) Other know active eye disease eye infection ( bacterial , fungal , viral ) may interfere evaluation uveitis . Grade 2 liver function abnormality Renal disease Any previous history immunodeficiency syndromes infection human immunodeficiency virus ( HIV ) , history hepatitis C chronic hepatitis B . Live viral bacterial vaccination within 3 month prior screen , plan receive vaccination trial , 3 month last injection MM093 . Pregnant breastfeed woman woman plan become pregnant study within 4 week last dose study drug . Scheduled elective surgery study participation Participated previous clinical trial use MM093 prior exposure MM093 . History severe hypersensitivity goat , sheep , cow milk product derive goat , sheep cow milk ( patient lactose intolerant exclude . ) Any acute clinically important condition investigator feel would jeopardize integrity study ( e.g . CTCAE grade 2 clinical find laboratory result . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>